Tocilizumab vs bevacizumab in critically ill COVID-19 patients: Registry-based prospective study
VEGF inhibitor bevacizumab led to significantly better ventilatory outcomes and lower in-hospital and 30-day deaths compared to IL-6 inhibitor tocilizumab in severely ill COVID-19 patients. Randomised studies are required to confirm these findings.
Authors
- Yatendra Gupta
- Gulam Mateen Parihar
- Pramod Sarwa
- Rajeev Gupta (ORCID: https://orcid.org/0000-0002-8356-3137)
- Anil Sharma
- Raghubir S Khedar
Institutions
- Eternal Hospital (IN)
Publication Details
- Journal
- The Journal of the Royal College of Physicians of Edinburgh
- Published
- 2025-11-12
- DOI
- https://doi.org/10.1177/14782715251394935
- Primary Topic
- COVID-19 Clinical Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00